Central Fill, GLP-1s, and Peptides: What Independent Pharmacies Need to Know

Sterile compounded medications, especially GLP-1 therapies like semaglutide and tirzepatide, have created one of the fastest-growing opportunities independent pharmacy has seen in years. In our latest Partnership Series webinar, Nicolette Mathey, PharmD, of Atrium24 walked our clients through why this market is growing, why so many pharmacies hesitate to get involved, and how to participate without taking on the cost and complexity of building a sterile compounding pharmacy from scratch. Here's a recap of what she covered and you can watch the full webinar recording here.

Why is this market growing?

Patient and prescriber demand for sterile injectable compounds has climbed steadily since GLP-1 therapies went mainstream. Patients have grown more comfortable with self-injection at home and that comfort is now spilling over into interest in other categories, particularly peptides used for wellness and longevity support. Nicolette noted that she expects the peptide market to eventually surpass the initial GLP-1 boom due to patient interest in longevity and wellness therapies.

What is central fill?

A common misconception is that only sterile compounding pharmacies can offer sterile compounded medications. This isn’t true. Any traditional retail (503A) pharmacy can dispense sterile compounded products by outsourcing the compounding function to another pharmacy through a central fill arrangement. The originating pharmacy (yours) sends the prescription securely to a vetted central fill partner, the partner compounds and fills it, and it's returned to you (or shipped directly to the patient, depending on your states licensure) for labeling, counseling, and dispensing. Central fill itself isn't new. What has changed is the increase in platform connectivity and technology that makes the workflow far less messy than it used to be.

“I don’t think my pharmacy can do that”…Three common hesitations

Nicolette walked through the objections she hears most often from pharmacy owners:

"Central fill is a messy workflow." In practice, it's a defined, compliant pathway rather than a workaround and better technology has made the handoff between pharmacies much cleaner than in years past. Several states, including New York, most recently, have passed shared pharmacy services laws that spell out exactly what's permissible and how labeling should be handled.

"I can't offer GLP-1s anymore." Compounded GLP-1s remain available when a prescriber documents legitimate medical necessity, patient-specific, on the prescription itself. That could mean an additive that reduces nausea, supports muscle mass, or improves tolerability, as long as the formulation differs meaningfully (more than 10%) from the commercially available product. It can never be justified on price alone. Some pharmacies choose not to dispense compounded GLP-1s at all due to state-specific concerns and that's a legitimate business decision too.

"Peptides aren't available yet." This one is partly true. Popular peptides such as BPC-157, TB-500, KPV, and MOTS-c are not currently on an FDA-authorized list and are not available through compliant channels today. However, the FDA's Pharmacy Compounding Advisory Committee is actively working through a rulemaking process that could add several of these to the 503A bulks list or Category 1 designation. Other peptides and wellness injectables, such as NAD+, sermorelin, and glutathione, are available today through vetted central fill partners.

Getting started without building a sterile pharmacy

Pharmacies have two paths into this space. The first is to build sterile compounding capability in-house: a clean room, specialized staffing and training, accreditations, and ongoing testing and compliance costs. Nicolette was candid that this only makes sense if sterile compounding is genuinely your focus, since the overhead is significant. The second path, and the one most of her audience is taking, is accessing central fill through a vetted partner network. That requires only a central fill agreement between your pharmacy and the central fill partner, and a secure way to transmit prescriptions. Atrium4's GPO connects member pharmacies to sterile compounding partners it has already vetted, including on-site visits and quarterly quality reviews, so pharmacies can add this service line without the accreditation burden.

Positioning for what's next

Nicolette's advice was to build the infrastructure now, before the next wave of authorized products arrives. Pharmacies that already have a central fill agreement and a way to track prescriber relationships will be ready to add newly authorized peptides the moment the FDA acts, without losing ground to competitors or online-only providers. Atrium24 also uses its DottiAI platform to help member pharmacies track prescriber relationships, profitability, and business development activity in one place, and the company is preparing to launch a CE-accredited peptide education series for pharmacists who want to get up to speed on the clinical and regulatory side.

If you'd like to watch Nicolette's full presentation, including her walkthrough of the DottiAI platform, you can find the webinar recording here

Where does R.J. Hedges & Associates Fit in?

A Compliance Note from R.J. Hedges & Associates: Because FDA guidance and enforcement policies surrounding compounded GLP-1 medications and peptides continue to evolve, pharmacies should carefully evaluate current federal and state requirements and the specific circumstances of each prescription before dispensing these products.

Exploring new opportunities doesn't mean your pharmacy has to do everything in-house. Strategic partnerships can help independent pharmacies expand the services they offer while allowing their teams to stay focused on the areas they know best. That's the philosophy behind the R.J. Hedges & Associates Partnership Series. We work with trusted industry partners like Atrium24 to connect independent pharmacies with resources, expertise, and opportunities that complement the compliance support we provide.

While R.J. Hedges & Associates does not provide a sterile compounding compliance program, we can help support the compliance foundation of your pharmacy through our Pharmacy Compliance Program, Non-Sterile Compounding Compliance Program, and other regulatory compliance services.

As you consider new service lines, partnerships, and opportunities for your pharmacy, we're here to help you navigate the compliance responsibilities that come with running and growing an independent pharmacy.

Ready to strengthen your pharmacy's compliance foundation? Contact R.J. Hedges & Associates to learn more about our pharmacy compliance programs and how we can help support your operation.